As of July 31, 2025, Dexcom G7 sensors and receivers will be officially listed under the Ontario Drug Benefit (ODB) program. This milestone expands access to real-time continuous glucose monitoring...

Diabetes Canada's March 2025 Clinical Practice Guidelines now recommend that all individuals living with type 1 diabetes (T1D) should use Automated Insulin Delivery (AID) systems, provided they are willing and...

The government-funded Saskatchewan Extended Benefits and Drug Plan has expanded coverage for real-time continuous glucose monitoring (rtCGM) systems. Newly included are the following groups of people who use insulin: People...

Dexcom has partnered with RxFood in supporting individuals living with diabetes by offering an integrated solution that combines industry-leading glucose monitoring system with an AI-powered nutrition app. This collaboration enables...

A recent clinical study 1 demonstrated that real-time continuous glucose monitoring (rtCGM) systems, like Dexcom G7, can offer substantial benefits to people living with type 2 diabetes (T2D) who are...

The American Diabetes Association (ADA) recently released its updated 2025 Standards of Care in Diabetes. 1 This comprehensive update reflects the latest evidence from clinical trials and research advancements in...

Dexcom now offers fasting glucose and post-meal glucose data in the Dexcom Clarity Clinic Web Portal. These features are designed to help you quickly identify where insulin or other medication...

The Dexcom G7 Continuous Glucose Monitoring (CGM) System now integrates with the Tandem t:slim X2 insulin pump with Control-IQ* technology. This pairing functions as an automated insulin delivery (AID) system...